Article

Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?

Department of Pediatrics, Children's Mercy Hospital and Clinics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
Journal of perinatology: official journal of the California Perinatal Association (Impact Factor: 2.35). 09/2011; 32(1):64-9. DOI: 10.1038/jp.2011.131
Source: PubMed

ABSTRACT The objective of this study is to determine the effects that sildenafil citrate has on gas exchange in infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH).
A retrospective review was performed from 2005 to 2009. Infants treated with sildenafil citrate for greater than 48  h were included. Standard patient data was collected, including echocardiogram, inspired oxygen and systemic blood pressure, before and during administration of sildenafil citrate.
Sildenafil citrate was used in 21 preterm infants with BPD-associated PH. A significant reduction in estimated right ventricular peak systolic pressure was seen after initiation of sildenafil citrate, with the majority of infants showing no improvement in gas exchange at 48  h of treatment. Four infants died during treatment.
Sildenafil citrate reduced estimated pulmonary artery pressures, but this reduction was not reflected in improved gas exchange within the first 48  h.

1 Follower
 · 
91 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is a significant contributor to perinatal morbidity and mortality. Premature birth disrupts pulmonary vascular growth and initiates a cascade of events that result in impaired gas exchange, abnormal vasoreactivity, and pulmonary vascular remodeling that may ultimately lead to pulmonary hypertension (PH). Even infants who appear to have mild BPD suffer from varying degrees of pulmonary vascular disease (PVD). Although recent studies have enhanced our understanding of the pathobiology of PVD and PH in BPD, much remains unknown with respect to how PH should be properly defined, as well as the most accurate methods for the diagnosis and treatment of PH in infants with BPD. This article will provide neonatologists and primary care providers, as well as pediatric cardiologists and pulmonologists, with a review of the pathophysiology of PH in preterm infants with BPD and a summary of current clinical recommendations for managing PH in this population.
    Pediatric Allergy, Immunology, and Pulmonology 03/2014; 27(1):8-16. DOI:10.1089/ped.2013.0323 · 0.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die pulmonale arterielle Hypertonie (PAH) im Kindesalter ist ein seltenes, aber schwerwiegendes Krankheitsbild. Der Phosphodiesterase-5-Hemmstoff Sildenafil gehört zu den wenigen zugelassenen Therapieoptionen für das Kindesalter. In einer aktuellen randomisierten, plazebokontrollierten Studie wurden seine Wirksamkeit und Sicherheit bei Kindern ab 1 Jahr untersucht, dabei konnte nur eine Effektivität beim mittleren Dosisregime gezeigt werden. In der darauf aufbauenden Langzeitsicherheitsstudie wurde eine dosisabhängige Erhöhung der Mortalitätsrate unter der Hochdosistherapie beobachtet. Obwohl in keinem Todesfall ein kausaler Zusammenhang mit Sildenafil gefunden wurde, sind weitere Studien notwendig, um den Stellenwert und das Nutzen-Risiko-Verhältnis der Therapie klar zu definieren. Die häufige Off-Label-Anwendung bei der persistierenden pulmonalen Hypertonie bei Neugeborenen, der bronchopulmonalen Dysplasie oder in Kombination mit dem Endothelinrezeptorantagonisten Bosentan beruht bisher auf schwacher Evidenz und fehlenden Langzeitstudien. Bis weitere Kenntnisse vorliegen, wird geraten, Kinder mit PAH nur innerhalb der zugelassenen Dosisempfehlung mit Sildenafil zu behandeln und den Off-Label-Gebrauch nur unter großer Vorsicht zu realisieren.
    Monatsschrift Kinderheilkunde 11/2013; 161(11). DOI:10.1007/s00112-013-2997-1 · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary hypertension, including pulmonary arterial hypertension (PAH), is a serious disease in children, but few clinical studies have been conducted to evaluate treatment regimens in this population. Currently, treatment of children with PAH is mostly based on clinical studies conducted in adults and a few dedicated pediatric studies. Sildenafil, a phosphodiesterase type 5 inhibitor, has an established efficacy and safety profile for the treatment of adults with PAH. In May 2011, sildenafil received approval for the treatment of pediatric patients aged 1-17 years in the EU; however, pediatric use is not approved in the USA. This systematic literature review summarizes the clinical data available on the use of sildenafil to treat children with PAH and pulmonary hypertension.
    Expert Review of Cardiovascular Therapy 09/2014; 12(10):1-28. DOI:10.1586/14779072.2014.958077

Full-text

Download
7 Downloads
Available from
Jan 26, 2015